Skip to main content

Table 2 Prognostic factors for time to radiologic progression in HCC patients treated with combination treatment

From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Characteristics NO. (N1 = 131) mTTP (month) Uni-variate HR (95%CI) p value Multi-variate HR1a (95%CI) p value Multi-variate HR2b (95%CI) p value
Gender (male/female) 112/19 7.3/7.2 0.923 (0.549–1.552) 0.763     
Age (< 60/≥60 years) 88/43 7.3/7.7 1.173 (0.774–1.776) 0.451     
Etiology (HBV/other than HBV) 108/23 7.3/7.2 1.065 (0.653–1.736) 0.802     
PLT (< 150/≥150 × 10E9/L) 74/57 7.8/5.6 0.925 (0.630–1.358) 0.691     
Albumin (< 35/≥35 g/L) 20/111 12.5/6.7 0.850 (0.483–1.494) 0.571     
Bilirubin (≥17/< 17 μmol/L) 50/81 6.9/8.3 1.159 (0.782–1.720) 0.462     
AST (≥40/< 40 U/L) 68/63 5.6/7.8 1.246 (0.851–1.823) 0.258     
ALT (≥40/< 40 U/L) 55/76 5.8/7.4 1.044 (0.708–1.540) 0.827     
AFP (≥200/< 200 ng/ml) 66/65 4.9/9.3 1.174 (0.800–1.723) 0.412     
Ascites (with/without) 15/116 5.7/7.3 1.291 (0.688–2.424) 0.426     
Child-Pugh score (5/6/≥7) 103/20/8 7.0/6/7/21.7 0.919 (0.641–1.316) 0.644     
Tumor size (≥7/< 7 cm) 70/61 5.4/10.8 1.646 (1.119–2.422) 0.011 1.900 (1.282–2.815) 0.001 1.834(1.239–2.741) 0.002
No. of HCC nodules (≥2/1) 62/69 5.4/9.6 1.338 (0.911–1.966) 0.137     
Sorafenib usage (after/before TACE) 43/88 7.9/7.2 0.998 (0.670–1.488) 0.993     
Vascularity (hypovascular/hypervascular) 43/88 3.7/10.2 2.643 (1.756–3.978) < 0.001 2.807 (1.848–4.265) < 0.001   
HFSR (non-responder/responder) 60/71 5.4/9.1 1.594 (1.084–2.343) 0.018 1.500 (1.031–2.221) 0.043   
Stratificationc
 Group A 52 12.2 1     1  
 Group BC 55 6.0 1.742 (1.127–2.693) 0.012    1.868 (1.205–2.896) 0.005
 Group D 24 2.9 3.741 (2.166–6.460) < 0.001    4.108 (2.362–7.145) < 0.001
  1. aMulti-variate HR1, variables of vascularity and 2HFSR60 were included in Cox-regression but not stratification
  2. bMulti-variate HR2, stratification was included after excepting vascularity and 2HFSR
  3. cGroup A: patients with both hypervascularity and HFSR-response; Group BC: patients with either hypervascularity or HFSR-response; Group D patients with hypovascularity and HFSR-nonresponse